The drug treatment of prostate cancer has evolved rapidly over the last few years—the metastatic castrate-resistant prostate cancer (mCRPC) setting has become crowded and competitive following the launch of five efficacious therapies since 2010, and the hormonal agents Zytiga (Johnson & Johnson/Janssen Biotech/Janssen-Cilag/AstraZeneca’s abiraterone) and Xtandi (Medivation/Astellas Pharma’s enzalutamide) compete fiercely in this setting. The prostate cancer drug development pipeline is dynamic, and agents in late-phase development span a wide range of drug classes. The expected launch of several emerging therapies for prostate cancer over 2015-2025 will heighten the competition, and it will be imperative for current and emerging therapies to differentiate and position themselves to maximize clinical and commercial success.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: 30 country-specific interviews with prostate cancer experts; physician surveys fielded to approximately 30 physicians (15 medical oncologists and 15 urologists) in the major markets.
Epidemiology: Diagnosed incidence of prostate cancer by risk for biochemical recurrence and TNM status. Clinical- and market-relevant drug-treatable populations.
Population segments in market forecast: Newly diagnosed low/intermediate risk (hormone-sensitive), newly diagnosed high/very high risk (hormone-sensitive), newly diagnosed metastatic (hormone-sensitive), biochemically recurrent (hormone-sensitive), nonmetastatic castrate-resistant, first-line metastatic castrate-resistant, second-line metastatic castrate-resistant, and third- and fourth-line metastatic castrate-resistant.
Emerging therapies: Phase I/II: 50 drugs; Phase III: 10 drugs.
Market forecast features: Using a proprietary patient-flow model, we forecast population sizes and drug sales for clinically and commercially relevant prostate cancer patient segments through 2025.